Zoetis Inc ZTS Analyst Rating Update - July 22, 2026
On July 22, 2026, Morgan Stanley maintained an Overweight rating on Zoetis (ZTS) while lowering the price target from $115 to $99, representing a 13.91% reduction.
- GF Valueâ„¢ verdict: Current Price $74.32 vs GF Valueâ„¢ $194.84 = 61.9% undervalued
- GF Scoreâ„¢: 76/100, indicating strong potential for long-term returns
- Insider activity shows $0.9M in buying over the last three months, with no selling activity.
What's Behind the Analyst Rating?
The recent adjustment by Morgan Stanley reflects a cautious sentiment among analysts regarding Zoetis ZTS. The downgrade in price target suggests that analysts are reassessing their expectations for the company amid changing market conditions. Despite the lowered target, the Overweight rating indicates that analysts still see potential for growth in the stock, albeit at a more tempered pace.
Zoetis Inc operates in the healthcare sector, specifically within the drug manufacturers industry. The company specializes in developing and manufacturing medicines and vaccines for animal health, generating approximately 35% of its revenue from production animals and 65% from companion animals. With a market capitalization of approximately $31.16 billion, Zoetis holds a leading position in the animal health market, having previously been part of Pfizer's animal health unit.
Is ZTS Overvalued or Undervalued?
According to GuruFocus, Zoetis ZTS has a GF Valueâ„¢ of $194.84, which indicates that the stock is currently trading at a significant discount with a margin of safety of 61.9%. This suggests that the stock may be undervalued relative to its intrinsic value, providing a potential opportunity for investors looking for growth in the animal health sector.
The stock's trailing twelve-month (TTM) P/E ratio stands at 12.33x, significantly lower than its 5-year median P/E of 35.11x. This disparity indicates that the stock may be undervalued based on historical performance metrics. For more insights, visit the GF Valueâ„¢ page.
What Does ZTS's GF Scoreâ„¢ Tell Us?
The GF Scoreâ„¢ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Scoreâ„¢ values have been found to generate higher long-term returns (backtested 2006-2021).
| Metric | Rating |
|---|---|
| GF Scoreâ„¢ | 76 |
| Financial Strength | 6/10 |
| Profitability | 10/10 |
| Growth | 8/10 |
| Valuation | 2/10 |
| Momentum | 2/10 |
Zoetis demonstrates strong profitability and growth potential, as evidenced by its perfect score in profitability (10/10) and a solid growth rank of 8/10. However, the valuation rank of 2/10 indicates that the stock may not be favorably priced compared to its earnings potential. For more details, visit the ZTS stock page.
What Are Insiders Doing with ZTS Stock?
In the past three months, insiders have shown confidence in Zoetis by purchasing approximately $0.9 million worth of shares, while there have been no reported sales. This insider buying could suggest that those closest to the company believe in its future prospects.
What This Means for Investors
In summary, while the recent analyst ratings reflect a cautious outlook for Zoetis ZTS, the company's strong GF Valueâ„¢ indicates that it is significantly undervalued. Investors may want to consider the potential for long-term growth in light of the favorable GF Scoreâ„¢ and insider buying activity.
For the complete analysis, visit the ZTS stock page. You can also use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions
What is ZTS's GF Scoreâ„¢?
ZTS's GF Scoreâ„¢ is 76/100, indicating a strong potential for long-term returns based on various financial metrics.
Is ZTS overvalued or undervalued?
ZTS is currently undervalued, with a GF Valueâ„¢ of $194.84 compared to its current price of $74.32, representing a 61.9% discount.
What do analysts recommend for ZTS?
Analysts generally maintain a positive outlook with an Overweight rating, despite recent price target reductions, suggesting potential for growth in the stock.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
